Concepedia

Publication | Open Access

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

DOIFull Paper Access

23

Citations

11

References

2020

Year

Richard B. Lipton, Joshua M. Cohen, Kristen Bibeau, Maja Galić, Michael J. Seminerio, Verena Ramirez Campos, Rashmi B. Halker Singh, Jessica Ailani
Headache The Journal of Head and Face Pain

Abstract

Fremanezumab may offer the benefit of reversion from CM to EM, based on a reduction in the number of headache days over 3 months of treatment.

References

YearCitations

Page 1